

Carlo Incerti, M.D.



Sr Vice President, Head of Genzyme Global Medical Affairs, Chief Medical Officer

Member of the EFPIA Board

Dr Incerti serves as Officer of Genzyme Corporation, where he oversees Global Medical Affairs, which includes Medical Operations, Global Regulatory Affairs and Compliance, Global Patient Safety and Risk Management, Patient Outcomes and Medical Economics.

The mission of the Global Medical Affairs Group is to facilitate and enable patient access for Genzyme's products through an integrated global strategy. GMA functional area operates as a continuum to enhance the value proposition of Genzyme's products, thus ensuring a successful 'product journey' from the development stage through the administration of therapy.

Dr Incerti is a Board Certified Endocrinologist, who started his career in the medical profession as a staff member and then as Associate Professor at the Department of Endocrinology of Modena University Hospital in Italy.

He joined Genzyme in 1992 as Medical Director Europe and then held various roles of increased responsibility in the R&D organisation.

In his tenure he was responsible for the development of all of the Genzyme products, with a specific focus on lysosomal storage disorders in the rare disease field. This development culminated in the successful approval in Europe of what is considered the first pre-orphan drug (Cerezyme for Gaucher disease), in the first officially approved orphan drug (Fabrazyme for Fabry disease) and in the first approved medicine obtained through DNA-recombinant technology in a transgenic animal (Atryn for antithrombin III deficiency).

Previous and other positions

- Carlo Incerti is currently President of the European Association for Bioindustries (EuropaBio)
- He is a member of the Board of EBE (European Biotechnology Enterprises), and was Chairman between 2006 and 2010
- He is currently a member of the Board of EFPIA (European Federation of Pharmaceutical Industries and Associations)
- Dr Incerti is a founding member of IRDiRC (International Rare Disease Research Consortium)